We open by marking Yom Kippur and a frank discussion before pivoting to the US 'MFN' drug-pricing moves, what they could mean for Australia’s PBS, and why institutional rigidity in HTA persists and is worsening. Medical research funding rhetoric versus slow progress in PBS and health technology access, hospital funding and NDIS pressures, and the expansion of pharmacist prescribing, as well as the need for subsidised pharmacy services. …
Latest Video
New Stories
-
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News -
Commercial outsourcing emerges as a strategic option to patient access
July 1, 2026 - - Latest News -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News